Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | -1.58M | -1.58M | 68.00K | 449.00K | -103.00K | -59.00K |
Gross Profit | -1.66M | -1.66M | -1.70M | 441.00K | -111.00K | -76.00K |
EBITDA | -2.62M | -1.75M | -1.88M | 381.00K | -160.00K | 0.00 |
Net Income | 54.81M | -1.75M | -1.88M | 381.00K | -160.00K | -110.00K |
Balance Sheet | ||||||
Total Assets | 7.47M | 7.47M | 9.21M | 1.73M | 1.34M | 1.49M |
Cash, Cash Equivalents and Short-Term Investments | 139.00K | 139.00K | 292.00K | 184.00K | 211.00K | 270.00K |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Liabilities | 93.00K | 93.00K | 83.00K | 24.00K | 15.00K | 11.00K |
Stockholders Equity | 7.38M | 7.38M | 9.13M | 1.70M | 1.32M | 1.48M |
Cash Flow | ||||||
Free Cash Flow | -235.50K | -157.00K | -210.00K | -70.00K | -59.00K | -71.00K |
Operating Cash Flow | -235.50K | -157.00K | -210.00K | -70.00K | -59.00K | -71.00K |
Investing Cash Flow | 6.00K | 4.00K | 52.00K | 68.00K | 0.00 | 295.00K |
Financing Cash Flow | 0.00 | 0.00 | 266.00K | -25.00K | 0.00 | -80.00K |
Oxford Technology 2 VCT Plc reported a decline in its net asset value for the quarter ending 30 November 2024, primarily due to decreased valuations of its key AIM quoted investments, Scancell Holdings and Arecor Therapeutics. Despite Scancell’s successful fundraising and new partnerships, the market has not reflected these positive developments. The company also faced a setback with Novacta Holdings entering administration, prompting a full provision against this investment. Meanwhile, Biocote Limited showed improved performance with increased sales. The board resolved concerns regarding remuneration policy with a major shareholder, indicating improved governance. The company did not declare dividends or engage in share transactions during the period.